Ken Katono

697 total citations
38 papers, 556 citations indexed

About

Ken Katono is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ken Katono has authored 38 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Ken Katono's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Ken Katono is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Ken Katono collaborates with scholars based in Japan, Australia and United States. Ken Katono's co-authors include Noriyuki Masuda, Shinichiro Ryuge, Yukitoshi Satoh, Yuichi Sato, Ryo Nagashio, Makoto Kobayashi, Satoshi Igawa, Shi-Xu Jiang, Makoto Saegusa and Sakiko Otani and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Ken Katono

37 papers receiving 549 citations

Peers

Countries citing papers authored by Ken Katono

Since Specialization

Citations

This map shows the geographic impact of Ken Katono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Katono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Katono more than expected).

Fields of papers citing papers by Ken Katono

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Katono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Katono. The network helps show where Ken Katono may publish in the future.

Co-authorship network of co-authors of Ken Katono

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Katono. A scholar is included among the top collaborators of Ken Katono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Katono. Ken Katono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016 2018 ·BMC Cancer ·Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, T. Oda, Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, (unknown), (unknown), Takeharu Yamanaka, Kentaro Sakamaki, Hiroaki Okamoto	9
2	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer 2017 ·Oncology ·Satoshi Igawa, Yuichi Sato, Shinichiro Ryuge, Masaaki Ichinoe, Ken Katono, Yasuhiro Hiyoshi, Sakiko Otani, Ryo Nagashio, (unknown), Masato Katagiri, Jiichiro Sasaki, Yoshiki Murakumo, Yukitoshi Satoh, Noriyuki Masuda	34
3	Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers 2017 ·PLoS ONE ·Shinichiro Ryuge, Yuichi Sato, Ryo Nagashio, Yasuhiro Hiyoshi, Ken Katono, Satoshi Igawa, (unknown), Kazu Shiomi, Masaaki Ichinoe, Yoshiki Murakumo, Makoto Saegusa, Yukitoshi Satoh, Noriyuki Masuda	7
4	S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma 2017 ·OncoTargets and Therapy ·Ken Katono, Yuichi Sato, Makoto Kobayashi, Ryo Nagashio, Shinichiro Ryuge, Satoshi Igawa, Masaaki Ichinoe, Yoshiki Murakumo, Makoto Saegusa, Noriyuki Masuda	20
5	Clinicopathological Significance of S100A10 Expression in Lung Adenocarcinomas 2016 ·Asian Pacific Journal of Cancer Prevention ·Ken Katono, Yuichi Sato, Shi-Xu Jiang, Makoto Kobayashi, Keita Saito, Ryo Nagashio, Shinichiro Ryuge, Yukitoshi Satoh, Makoto Saegusa, Noriyuki Masuda	24
6	Endobronchial involvement of mantle cell lymphoma: A case report 2016 ·Respiratory Medicine Case Reports ·Ken Katono, Masayuki Shirasawa, (unknown), (unknown), Yoshiro Nakahara, Satoshi Igawa, Masanori Yokoba, Masaru Kubota, Noriyuki Masuda	6
7	Calnexin is a novel sero-diagnostic marker for lung cancer 2015 ·Lung Cancer ·Makoto Kobayashi, Ryo Nagashio, Shi-Xu Jiang, Keita Saito, Benio Tsuchiya, Shinichiro Ryuge, Ken Katono, (unknown), Eriko Fukuda, Naoki Goshima, Yukitoshi Satoh, Noriyuki Masuda, Makoto Saegusa, Yuichi Sato	34
8	Prognostic Significance of MYH9 Expression in Resected Non-Small Cell Lung Cancer 2015 ·PLoS ONE ·Ken Katono, Yuichi Sato, Shi-Xu Jiang, Makoto Kobayashi, Ryo Nagashio, Shinichiro Ryuge, Eriko Fukuda, Naoki Goshima, Yukitoshi Satoh, Makoto Saegusa, Noriyuki Masuda	46
9	Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma 2015 ·Asian Pacific Journal of Cancer Prevention ·(unknown), Ryo Nagashio, Shinichiro Ryuge, Ken Katono, Shi‐Xu Jiang, Benio Tsuchiya, (unknown), Eriko Fukuda, Naoki Goshima, Makoto Saegusa, Yukitoshi Satoh, Noriyuki Masuda, Yuichi Sato	5
10	Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report 2015 ·Oncology Letters ·Satoshi Igawa, Nobuyuki Yanagisawa, (unknown), (unknown), Yasuhiro Hiyoshi, Sakiko Otani, Ken Katono, Jiichiro Sasaki, Yukitoshi Satoh, Noriyuki Masuda	8
11	S100A16 is a Prognostic Marker for Lung Adenocarcinomas 2015 ·Asian Pacific Journal of Cancer Prevention ·Keita Saito, Makoto Kobayashi, Ryo Nagashio, Shinichiro Ryuge, Ken Katono, (unknown), Benio Tsuchiya, Shi-Xu Jiang, Makoto Saegusa, Yukitoshi Satoh, Noriyuki Masuda, Yuichi Sato	28
12	Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer 2015 ·Scientific Reports ·Ryo Nagashio, (unknown), Shinichiro Ryuge, (unknown), Shi-Xu Jiang, Makoto Kobayashi, (unknown), Ken Katono, Yukitoshi Satoh, Noriyuki Masuda, Yoshiki Murakumo, (unknown), Yuichi Sato	45
13	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation 2014 ·Cancer Chemotherapy and Pharmacology ·Satoshi Igawa, Masashi Kasajima, (unknown), Michiko Kimura, Yasuhiro Hiyoshi, (unknown), (unknown), (unknown), (unknown), Sakiko Otani, Ken Katono, Jiichiro Sasaki, Noriyuki Masuda	10
14	Circulating tumor cells as a prognostic factor in patients with small cell lung cancer 2014 ·Oncology Letters ·Satoshi Igawa, Keigo Gohda, Tomoya Fukui, Shinichiro Ryuge, Sakiko Otani, (unknown), Jun Sato, Katsuhiro Murakami, S. Maki, Ken Katono, Akira Takakura, Jiichiro Sasaki, Yukitoshi Satoh, Noriyuki Masuda	56
15	Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation 2014 ·Oncology ·Satoshi Igawa, Masashi Kasajima, (unknown), Michiko Kimura, Yasuhiro Hiyoshi, (unknown), Sakiko Otani, Ken Katono, Jiichiro Sasaki, Noriyuki Masuda	12
16	Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer 2013 ·Chemotherapy ·Satoshi Igawa, Jiichiro Sasaki, (unknown), Sakiko Otani, S. Maki, Yasuhiro Hiyoshi, Masashi Kasajima, Ken Katono, Akira Takakura, Noriyuki Masuda	5
17	Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer 2012 ·Cancer Chemotherapy and Pharmacology ·(unknown), Michiko Yamamoto, (unknown), Shinichiro Ryuge, Ken Katono, Masanori Yokoba, Tomoya Fukui, Akira Takakura, Sakiko Otani, S. Maki, Satoshi Igawa, (unknown), Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Noriyuki Masuda	4
18	Prognostic Significance of Nestin Expression in Resected Non-small Cell Lung Cancer 2010 ·CHEST Journal ·Shinichiro Ryuge, Yuichi Sato, (unknown), Toshihide Matsumoto, (unknown), Ken Katono, (unknown), Yukitoshi Satoh, Noriyuki Masuda	40
19	Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer 2010 ·International Journal of Clinical Oncology ·Satoshi Igawa, Shinichiro Ryuge, Tomoya Fukui, Sakiko Otani, (unknown), Ken Katono, Akira Takakura, Masaru Kubota, Hisashi Mitsufuji, Masato Katagiri, (unknown), Noriyuki Masuda	13
20	Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan 2009 ·SHILAP Revista de lepidopterología ·Shinichiro Ryuge, Shi-Xu Jiang, (unknown), Ken Katono, et al., (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact